Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes

Abstract C-Mannosyl tryptophan (CMW) is a unique glycosylated amino acid, and a candidate novel biomarker of renal function. In type 2 diabetes (T2D), a combination of metabolites including CMW has recently been the focus of novel biomarkers for the evaluation of renal function and prediction of its...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuhei Morita, Yoko Inai, Shiho Minakata, Shohei Kishimoto, Shino Manabe, Naoyuki Iwahashi, Kazuhiko Ino, Yukishige Ito, Takashi Akamizu, Yoshito Ihara
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/48361f48a99444bc861e2f9a730ac928
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:48361f48a99444bc861e2f9a730ac928
record_format	dspace
spelling	oai:doaj.org-article:48361f48a99444bc861e2f9a730ac9282021-12-02T15:23:29ZQuantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes10.1038/s41598-021-81479-y2045-2322https://doaj.org/article/48361f48a99444bc861e2f9a730ac9282021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81479-yhttps://doaj.org/toc/2045-2322Abstract C-Mannosyl tryptophan (CMW) is a unique glycosylated amino acid, and a candidate novel biomarker of renal function. In type 2 diabetes (T2D), a combination of metabolites including CMW has recently been the focus of novel biomarkers for the evaluation of renal function and prediction of its decline. However, previous quantification methods for serum CMW have several limitations. We recently established a novel assay for quantifying serum CMW. Serum CMW from 99 Japanese patients with T2D was quantified by this assay using hydrophilic interaction liquid chromatography. The serum CMW levels were cross-sectionally characterized in relation to clinical features, including renal function and vascular complications. Serum CMW level was more strongly correlated with serum creatinine and cystatin C levels and with eGFR than with albumin urea level. The ROC curve to detect eGFR < 60 ml/min/1.73 m2 revealed that the cutoff serum CMW level was 337.5 nM (AUC 0.883). Serum CMW levels were higher in patients with a history of macroangiopathy than in those without history. They correlated with ankle-brachial pressure index, whereas cystatin C did not. Serum CMW levels quantified by the novel assay could be useful in evaluation of glomerular filtration of renal function and peripheral arterial disease in T2D.Shuhei MoritaYoko InaiShiho MinakataShohei KishimotoShino ManabeNaoyuki IwahashiKazuhiko InoYukishige ItoTakashi AkamizuYoshito IharaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shuhei Morita Yoko Inai Shiho Minakata Shohei Kishimoto Shino Manabe Naoyuki Iwahashi Kazuhiko Ino Yukishige Ito Takashi Akamizu Yoshito Ihara Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
description	Abstract C-Mannosyl tryptophan (CMW) is a unique glycosylated amino acid, and a candidate novel biomarker of renal function. In type 2 diabetes (T2D), a combination of metabolites including CMW has recently been the focus of novel biomarkers for the evaluation of renal function and prediction of its decline. However, previous quantification methods for serum CMW have several limitations. We recently established a novel assay for quantifying serum CMW. Serum CMW from 99 Japanese patients with T2D was quantified by this assay using hydrophilic interaction liquid chromatography. The serum CMW levels were cross-sectionally characterized in relation to clinical features, including renal function and vascular complications. Serum CMW level was more strongly correlated with serum creatinine and cystatin C levels and with eGFR than with albumin urea level. The ROC curve to detect eGFR < 60 ml/min/1.73 m2 revealed that the cutoff serum CMW level was 337.5 nM (AUC 0.883). Serum CMW levels were higher in patients with a history of macroangiopathy than in those without history. They correlated with ankle-brachial pressure index, whereas cystatin C did not. Serum CMW levels quantified by the novel assay could be useful in evaluation of glomerular filtration of renal function and peripheral arterial disease in T2D.
format	article
author	Shuhei Morita Yoko Inai Shiho Minakata Shohei Kishimoto Shino Manabe Naoyuki Iwahashi Kazuhiko Ino Yukishige Ito Takashi Akamizu Yoshito Ihara
author_facet	Shuhei Morita Yoko Inai Shiho Minakata Shohei Kishimoto Shino Manabe Naoyuki Iwahashi Kazuhiko Ino Yukishige Ito Takashi Akamizu Yoshito Ihara
author_sort	Shuhei Morita
title	Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
title_short	Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
title_full	Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
title_fullStr	Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
title_full_unstemmed	Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
title_sort	quantification of serum c-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/48361f48a99444bc861e2f9a730ac928
work_keys_str_mv	AT shuheimorita quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT yokoinai quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT shihominakata quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT shoheikishimoto quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT shinomanabe quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT naoyukiiwahashi quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT kazuhikoino quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT yukishigeito quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT takashiakamizu quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes AT yoshitoihara quantificationofserumcmannosyltryptophanbynovelassaytoevaluaterenalfunctionandvascularcomplicationsinpatientswithtype2diabetes
_version_	1718387261524934656

Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes

Ejemplares similares